Search Results

Containing any of the words

Only of the type

An Update in the Prescribing Information of Exubera Awareness Article

ALLOPURINOL (PURINOL, ZYLORIC) AND LIFE-THREATENING STEVENS-JOHNSON SYNDROME OR TOXIC EPIDERMAL NECROLYSIS Awareness Article

A Phase IV Double-Blind Placebo-Controlled Randomized Clinical Trial Assessing the Effect of 2 month consumption of Vetal Laban Including Lactobacillus acidophilus NCFM on Functional Gastrointestinal Symptoms Among Subjects Fulfilling Rome III Criteria for A Phase IV, Randomized, double-blind, placebo-controlled study with parallel groups Irritable Bowel Syndrome Drug Clinical Trial

Post-authorization safety study in patients with type 2 diabetes mellitus to assess the incidence of ketoacidosis, severe complications of urinary tract infection, volume depletion, and dehydration among patients treated with EMPAGLIFLOZIN or DPP-4 inhibitors in Saudi Arabia Drug Clinical Trial

Is it possible to extend the period of informing the customers for more than 5 working days if we have large number of affected users? FAQ

O-SEMA-Fast: A research study to understand how oral semaglutide works in people with type 2 diabetes who plan to fast during Ramadan in the United Arab Emirates, Saudi Arabia, and Kuwait Drug Clinical Trial

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis Awareness Article

A Retrospective Observational Non-Interventional Study (NIS) to assess Patient Characteristics and Healthcare Resource Use (HCRU) among COVID-19 Patients Receiving Treatment with Nirmatrelvir; Ritonavir (PAXLOVIDTM) in the Kingdom of Saudi Arabia (KSA) Drug Clinical Trial

A Phase III, Multicentre, Randomised, Double blind, Parallel group, Placebo controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA) Drug Clinical Trial

A Phase 3 Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial with Open Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjögren’s Disease Drug Clinical Trial